Nathan Johnson, Chris Evans and Aisling Ryan continue their work with their colleagues to advance the Living with Idiopathic Pulmonary Fibrosis (L-IPF) tool through the FDA’s qualification process.  The most recent results of that research were presented as an Encore presentation at the Pulmonary Fibrosis Foundation Summit in Nashville on November 9, 2017.